# OnCo record trastuzumab-emtansine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trastuzumab-emtansine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trastuzumab-emtansine" ;
  schema:name "Trastuzumab emtansine"@en ;
  schema:description "Trastuzumab emtansine (Kadcyla, T-DM1) was the first ADC for a solid tumour (2013). It is still standard after surgery for HER2+ breast cancer patients whose tumour did not fully respond to pre-surgery treatment."@en ;
  schema:url <https://onco.cc/drugs/trastuzumab-emtansine/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trastuzumab_emtansine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3997863> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20emtansine> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Kadcyla" ;
  onco:approval "US 2013: HER2+ metastatic breast cancer after trastuzumab and taxane", "US 2019: Adjuvant HER2+ breast cancer with residual disease after neoadjuvant therapy" ;
  onco:related <https://onco.cc/biomarkers/her2-ihc-3-plus/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/smcc/> ;
  onco:trials <https://onco.cc/trials/nct06313086/>, <https://onco.cc/trials/nct06830889/>, <https://onco.cc/trials/nct06316531/>, <https://onco.cc/trials/nct05081609/>, <https://onco.cc/trials/nct06324357/>, <https://onco.cc/trials/nct04931342/>, <https://onco.cc/trials/nct04873362/>, <https://onco.cc/trials/nct00781612/>, <https://onco.cc/trials/nct06126640/> .